Lakewood-Amedex Biotherapeutics announced positive Minimum Inhibitory Concentration (MIC) data for its lead candidate, Nu-3, demonstrating consistent activity against various organisms and a favorable therapeutic window. This data supports the ongoing Phase 2a clinical trial for diabetic foot ulcers, with topline results expected in Q1 2027, potentially de-risking the drug's development.
Lakewood-Amedex Biotherapeutics (LABT) reported positive MIC data for its antimicrobial candidate, Nu-3, showing consistent activity against various clinical isolates and a strong therapeutic window. This is a significant de-risking event for the company's lead asset, as it provides further validation of Nu-3's efficacy ahead of topline Phase 2a data expected in Q1 2027. For LABT, this news is a positive catalyst, potentially increasing investor confidence and attracting further interest in the stock. Short-term, it could lead to a modest upward movement in share price, while long-term implications depend on the eventual Phase 2a results and subsequent development. The key opportunity for traders is the potential for continued positive momentum if future clinical milestones are met.